Acadia Pharma starts Phase 3 in Prader-Willi Syndrome

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the United States.^1-4 The most common symptom is hyperphagia, which is an unrelenting lack of satiety. Other defining features of PWS may include altered metabolism, developmental delays, behavioral challenges and moderate cognitive deficits.

https://www.biospace.com/article/releases/acadia-pharmaceuticals-initiates-pivotal-phase-3-study-of-carbetocin-acp-101-for-the-treatment-of-hyperphagia-in-prader-willi-syndrome/